Adamis Pharmaceuticals Corporation (ADMP)
Stock Price:
$1.14 USD
-0.09 (-7.32%)
Updated Aug 11, 2020 4:00 PM EDT - Market closed
After-hours: $1.11 -0.03 (-2.63%) Aug 11, 7:58 PM
Key Info
| Market Cap |
84.27M |
| Revenue (ttm) |
21.87M |
| Net Income (ttm) |
-30.69M |
| Shares Out |
73.92M |
| EPS (ttm) |
-0.53 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 11, 2020 |
| Last Price |
$1.14 |
| Previous Close |
$1.23 |
| Change ($) |
-0.09 |
| Change (%) |
-7.32% |
| Day's Open |
1.20 |
| Day's Range |
1.11 - 1.22 |
| Day's Volume |
3,736,916 |
| 52-Week Range |
0.27 - 1.51 |
More Stats
| Market Cap |
84.27M |
| Enterprise Value |
77.71M |
| Earnings Date (est) |
Nov 17, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
73.92M |
| Float |
72.66M |
| EPS (basic) |
-0.51 |
| EPS (diluted) |
-0.53 |
| FCF / Share |
-0.26 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
3.42M |
| Short Ratio |
1.63 |
| Short % of Float |
6.17% |
| Beta |
2.47 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
3.85 |
| PB Ratio |
2.74 |
| Revenue |
21.87M |
| Operating Income |
-30.67M |
| Net Income |
-30.69M |
| Free Cash Flow |
-17.33M |
| Net Cash |
6.56M |
| Net Cash / Share |
0.09 |
| Gross Margin |
28.86% |
| Operating Margin |
-140.23% |
| Profit Margin |
-140.30% |
| FCF Margin |
-79.22% |
| ROA |
-35.13% |
| ROE |
-84.10% |
| ROIC |
-209.60% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (3)
| Buy |
2 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$1.25*
(9.65% upside)
Low
1.00
Current: $1.14
High
1.50
Target: 1.25
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|
| Revenue | 22.11 | 15.09 | 13.07 | 6.47 | - | - | - | - | - | 0.29 |
| Revenue Growth | 46.58% | 15.4% | 101.94% | - | - | - | - | - | - | - |
| Gross Profit | 6.64 | 5.29 | 5.65 | 1.62 | - | - | - | - | - | 0.03 |
| Operating Income | -29.35 | -39.46 | -24.69 | -25.20 | -13.85 | -4.40 | -3.22 | -4.82 | -6.24 | -3.98 |
| Net Income | -29.31 | -39.01 | -25.54 | -19.44 | -13.57 | -8.16 | -7.19 | -4.92 | -6.98 | -6.71 |
| Shares Outstanding | 53.26 | 39.09 | 28.35 | 17.50 | 13.28 | 7.35 | 5.86 | 5.26 | 3.75 | 1.70 |
| Earnings Per Share | -0.55 | -1.00 | -0.90 | -1.19 | -1.03 | -1.22 | -1.23 | -1.02 | -1.87 | -3.91 |
| Operating Cash Flow | -19.89 | -32.66 | -15.13 | -21.16 | -10.34 | -6.78 | -2.56 | -3.35 | -4.31 | -2.00 |
| Capital Expenditures | -2.87 | -3.54 | -2.06 | -0.12 | - | -0.10 | - | - | - | - |
| Free Cash Flow | -22.75 | -36.19 | -17.19 | -21.28 | -10.34 | -6.88 | -2.56 | -3.35 | -4.31 | -2.00 |
| Cash & Equivalents | 8.81 | 19.27 | 18.33 | 5.10 | 4.08 | 5.40 | 0.00 | 0.01 | 1.24 | 0.29 |
| Total Debt | 4.08 | 2.58 | 5.07 | 7.40 | - | 0.42 | 1.18 | 0.30 | 1.36 | 1.78 |
| Net Cash / Debt | 4.73 | 16.69 | 13.27 | -2.30 | 4.08 | 4.98 | -1.18 | -0.29 | -0.12 | -1.49 |
| Assets | 47.84 | 58.36 | 51.40 | 37.79 | 12.06 | 15.12 | 0.35 | 0.17 | 1.73 | 0.68 |
| Liabilities | 11.80 | 11.67 | 11.86 | 12.51 | 2.75 | 2.93 | 4.68 | 2.89 | 3.11 | 4.95 |
| Book Value | 36.04 | 46.69 | 39.55 | 25.28 | 9.31 | 12.19 | -4.33 | -2.72 | -1.38 | -4.27 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Adamis Pharmaceuticals Corporation |
| Country |
United States |
| Employees |
131 |
| CEO |
Dennis J. Carlo |
Stock Information
| Ticker Symbol |
ADMP |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Drug Delivery |
| Unique Identifier |
NASDAQ: ADMP |
Description
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis. It also offers dry powder inhaler products consisting of fluticasone (APC-4000) for the treatment of asthma; beclomethasone (APC-1000), a metered dose inhaler product for the asthma; Tadalafil (APC-8000) for the treatment of erectile dysfunction; and naloxone injection product candidates (APC-6000) for the treatment of opioid overdose. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, injectables, urological preparations, topical compounds for pain, and men's and women's health products; and certain veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation is headquartered in San Diego, California.